All News

Compared with sorafenib, a combination of sintilimab and a bevacizumab biosimilar improved responses in patients with unresectable hepatocellular carcinoma (HCC).

The researchers note that this finding adds valuable insight for individualized treatment decisions in scenarios where the role of thymectomy is not fully clear.

In an animal study, researchers found that valproate, a common epilepsy drug, possessed hypnotic and antiepileptic properties during sleep, suggesting that the drug could help improve sleep quality for patients with nocturnal epilepsy.

Trouble with balance and holding objects above one's head were just a few of the problems reported by patients 3 years before they received a formal Parkinson disease diagnosis, according to a recent study.

Clarivate’s “Drugs to Watch” list for 2023 mentions 15 therapeutics, including teplizumab for type 1 diabetes (T1D).

A recent study found that ixazomib was associated with better progression-free survival versus a placebo in multiple myeloma regardless of cytogenetic risk status.

A recent study aggregated RNA sequencing data from more than 3000 samples to create a user-friendly database of transcription profiles in leukemia and related cell lines.

The systemic review and meta-analysis, believe the researchers, is the first of its kind to characterize the prevalence of depression among these patients.

A new study highlighted that patients with diabetes enrolled in Medicare Advantage (MA) had better outcomes compared with patients in traditional fee-for-service (FFS) Medicare.

Timothy Murphy, MD, FACP, current practice president at Rocky Mountain Cancer Centers, spoke with The American Journal of Managed Care® about the current state of lung cancer screenings.

As the country hits the debt limit spending on Medicare and Medicaid may be at risk; the Agriculture Department targets fraudulent claims in products labeled as organic; first cases of drug-resistant gonorrhea strain found.

A study found that adherence to the CDC recommendation of mRNA monovalent COVID-19 boosters was low in immunocompromised individuals.

According to Eli Lilly's statement, the investigational drug worked quickly, so too few patients in the phase 2 study took it for a full year.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Progressive muscle relaxation exercises may improve depression, sleep, and quality of life in patients with epilepsy.

The study sought to identify what factors were linked with developing depression in adults with asthma without a history of the disease, and to identify which factors were associated with recurrent depression during the pandemic in adults with both conditions.

Although it is well studied in adult patients, there is a lack of research on eosinophilic gastrointestinal disorders (EGIDs) among pediatric patients; a recent study aimed to add to the clinical knowledge of EGIDs in younger patients.

The broad approval, while expected, will likely signal a milestone in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The combination of tucatinib and trastuzumab received accelerated approval from the FDA to treat adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (mCRC) that advances after treatment with specific types of chemotherapy.

A small study conducted in China suggests pregnant women with idiopathic pulmonary arterial hypertension (iPAH) are at higher risk of maternal mortality compared with women with certain other types of pulmonary hypertension (PH).

Frequent visits to green spaces may be associated with lower use of asthma, mental health, and high blood pressure medication in urban environments.

A perspective article discussed the possible approaches that scientists can take in developing a new generation of vaccines to fight against several respiratory viruses.

Johnson & Johnson (J&J) ends late-stage HIV vaccine trial; mothers in states with abortion bans are almost 3 times more likely to die before, during, and after birth; Sanofi hopes to release a drug for hemophilia A in 2023.

A Q-TWiST analysis of ZUMA-7 trial data suggests that axicabtagene ciloleucel (axi-cel) in the second line is beneficial to quality-adjusted survival and is a viable option for patients with relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy.

A review explored clinical considerations related to the pathogenesis, diagnosis, and management of idiopathic hypersomnia.

Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.

This new investigation serves to update decades-old data on patient eligibility for and participation in cardiac rehabilitation programs.

Patients with chronic obstructive pulmonary disease (COPD) are more likely to die in the year after undergoing surgery and rack up higher health care costs post-operation, study finds.

The new National Comprehensive Cancer Network (NCCN) forum on equity aims to improve diversity of clinical staff representation across the nation’s leading academic cancer centers.

A preplanned analysis of the PACIFIC-R confirms findings from the pivotal PACIFIC trial of durvalumab as consolidation therapy in unresectable NSCLC after chemoradiotherapy.